Longer duration of treatment with methylprednisolone for acute hepatic cell rejection following liver transplant–followed by tapering the dose–appears to be safer and more effective than a shorter duration at the same dose with no tapering.
Researchers at the University of Padua, Italy, note that dosing schedules for intravenous methylprednisolone following liver transplant are derived from those developed for acute renal cell rejection.
For that reason, they studied the two schedules most widely used to compare for safety and efficacy following liver transplant.
Thirty-eight patients with grade II or III acute hepatic cellular rejection were randomized to receive an intravenous dose of 1,000 mg of methylprednisolone followed by a six-day taper from 200 to 20 mg/d (n=18), or 1,000 mg of methylprednisolone for three consecutive days (n=20).
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!